The Efficacy and Safety of Endostatin Combined with Definitive Chemoradiotherapy for Unresectable Esophageal Squamous Cell Carcinoma: A Retrospective Analysis
Authors:
Open Access
- 25 October 2025
- journal article
- Published by The Korean Society of Gastroenterology in The Korean Journal of Gastroenterology
- Vol. 85 (4) , 497-505
Abstract
Mengyuan Zhu, Qun Li and Xiaofen Pan. Korean J Gastroenterol 2025;85:497-505. https://doi.org/10.4166/kjg.2024.150Keywords
This publication has 27 references indexed in Scilit:
- Efficacy of Concurrent Chemoradiotherapy With S-1 vs Radiotherapy Alone for Older Patients With Esophageal CancerJAMA Oncology, 2021
- Radiation Dose-escalated Chemoradiotherapy Using Simultaneous Integrated Boost Intensity-Modulated Radiotherapy for Locally Advanced Unresectable Thoracic Oesophageal Squamous Cell Carcinoma: A Single-institution Phase I StudyClinical Oncology, 2021
- Recent progress in multidisciplinary treatment for patients with esophageal cancerSurgery Today, 2019
- Current Status and Study Progress of Recombinant Human Endostatin in Cancer TreatmentOncology and Therapy, 2018
- Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal CancerJAMA Oncology, 2017
- RECIST 1.1—Update and clarification: From the RECIST committeeEuropean Journal of Cancer, 2016
- Enhanced radioresponse with a novel recombinant human endostatin protein via tumor vasculature remodeling: Experimental and clinical evidenceRadiotherapy and Oncology, 2013
- Failure patterns in patients with esophageal cancer treated with definitive chemoradiationCancer, 2011
- Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center studyRadiotherapy and Oncology, 2005
- Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinomaCancer, 2003